Updated guidance on when chemotherapy is used for breast cancer, how it is given, how it fits with targeted and hormonal treatments, common side effects, and fertility considerations.
Primary peritoneal carcinoma (PPC) arises from the abdominal lining and behaves much like epithelial ovarian cancer. Diagnosis uses imaging, CA-125, and biopsy. Standard care remains cytoreductive surgery plus platinum-based chemotherapy; PARP inhibitors are now commonly used as maintenance in eligible patients. Long-term surveillance and genetic testing are important.
Primary peritoneal carcinoma is a rare, ovarian-type cancer of the abdominal lining. It causes vague symptoms such as bloating and abdominal pain and is treated like advanced ovarian cancer with surgery, platinum-based chemotherapy, and, when appropriate, targeted therapies including PARP inhibitors.
Chemotherapy remains an important option for advanced prostate cancer, especially when disease becomes resistant to hormonal therapy or in selected men with extensive metastatic disease. This update explains when chemo is used, common drugs, side effects, and how it fits with newer targeted and immune therapies.
An updated overview of prostate cancer management: screening choices, active surveillance, local and systemic treatments including newer targeted and radioligand therapies, and realistic guidance on diet, supplements, and lifestyle.
Practical, evidence-based ways to manage prostate cancer: how surveillance, surgery, radiation, systemic drugs, lifestyle, and mental-health support fit together.
A concise, updated overview of prostate anatomy, detection (PSA and DRE), treatment options from active surveillance to surgery, radiation, hormone therapies, and newer targeted options for advanced disease.
Modern ovarian cancer treatment combines surgery, platinum-based chemotherapy, and targeted maintenance therapies guided by tumor genetics and patient priorities. Multidisciplinary care, genetic testing, and clinical trials shape individualized plans.
Prostate cancer treatment is individualized by stage and risk. Early disease may be monitored with active surveillance or treated with surgery or radiation. Advanced disease relies on androgen-deprivation, systemic targeted agents, chemotherapy, and radioligand therapy, with decisions guided by biomarkers and patient goals.